A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Investigator: Monisha Singh, MD

Study Coordinator: Michelle Prystash

Status: Enrolling

ClinicalTrials.gov Number: NCT03059823

Phone: 713.441.6564

Protocol Number: Pro00020780


The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012 will also be assessed.
More to Explore
Live Chat Available